


# PRODUCT INFORMATION



## LAS191859

Item No. 20238

**CAS Registry No.:** 1420071-13-1  
**Formal Name:** 1-[2-[(cyclopropylcarbonyl)ethylamino]methyl]-4-(trifluoromethyl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-acetic acid  
**MF:** C<sub>24</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>  
**FW:** 459.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 272 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

LAS191859 is supplied as a crystalline solid. A stock solution may be made by dissolving the LAS191859 in the solvent of choice. LAS191859 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of LAS191859 in ethanol is approximately 2.5 mg/ml and approximately 20 mg/ml in DMSO and DMF.

LAS191859 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LAS191859 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. LAS191859 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

LAS191859 is a potent antagonist of CRTH2/DP<sub>2</sub> with IC<sub>50</sub> values of 9.58, 14, 15.5, and 7.6 nM for recombinant human, rat, mouse, and guinea pig CRTH2/DP<sub>2</sub> receptors, respectively.<sup>1</sup> It is selective for CRTH2/DP<sub>2</sub> over a panel of 65 enzymes, ion channels, and transporters with <25% inhibition for all targets when tested at a concentration of 10 μM. LAS191859 reduces shape change of eosinophils (IC<sub>50</sub>s = 2 and 8.2 nM in isolated eosinophils and whole blood, respectively) and eosinophil chemotaxis (IC<sub>50</sub> = 1.3 nM) induced by prostaglandin D<sub>2</sub> (PGD<sub>2</sub>; Item No. 12010) binding to CRTH2/DP<sub>2</sub>. Oral administration of LAS191859 reduces PGD<sub>2</sub>-induced systemic eosinophilia in guinea pigs (ID<sub>50</sub> = 131 μg/kg).

### Reference

1. Calbet, M., Andrés, M., Armengol, M., *et al.* Pharmacological characterization of CRTH2 antagonist LAS191859: Long receptor residence time translates into long-lasting in vivo efficacy. *Pharmacol. Res.* **111**, 208-216 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/18/2017

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM